Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 1983 Aug;62(2):315-9
Date
08/01/1983Pubmed ID
6575837Scopus ID
2-s2.0-0020511359 (requires institutional sign-in at Scopus site) 201 CitationsAbstract
We designed a protocol (VAPA) that featured 14 mo of intensive postremission induction chemotherapy in an effort to improve remission durations for patients with acute myelogenous leukemia (AML). One hundred and seven patients under 50 yr of age were entered into this study. The rate of complete remission is 70%. A Kaplan-Meier analysis of patients entering remission predicts that 56% +/- 7% (+/-SE) of patients less than 18 yr and 45% +/- 9% of patients aged 18-50 yr will remain in remission at 3 yr (median follow-up is 43 mo). Patients with the monocytic subtype had a statistically significant shorter duration of remission (2-sided p less than 0.05). There was a high incidence of primary CNS relapse in children. Thirty-one of 41 patients who completed the regimen remain in remission without maintenance therapy. We conclude that the VAPA protocol continues to offer a promising approach to treatment of AML.
Author List
Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RDMESH terms used to index this publication - Major topics in bold
AdultAgranulocytosis
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Brain Neoplasms
Child
Cytarabine
Doxorubicin
Drug Therapy, Combination
Humans
Leukemia, Myeloid, Acute
Prednisolone
Vincristine